George A Zakhem1, Julia E Goldberg1, Catherine C Motosko1, Brandon E Cohen2, Roger S Ho3. 1. Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York. 2. Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California. 3. Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York. Electronic address: roger.ho@nyumc.org.
Abstract
BACKGROUND: Prescription medications are among the most common causes of sexual dysfunction, and patients are often hesitant to seek help when experiencing these symptoms. OBJECTIVE: In this review, we identify the available evidence of sexual adverse effects in men using systemic dermatologic medications and suggest screening protocols and actions that may improve a patient's symptoms where possible. METHODS: A systematic review was conducted of all articles in the PubMed database published from the time of inception to May 2018 to identify studies evaluating the use of systemic dermatologic medications in men with evidence of sexual adverse effects. Subsequently, a secondary in-depth literature review was performed for each individual medication. RESULTS: There were 5497 articles reviewed in the primary systematic review, and 59 articles covering 11 systemic dermatologic medications met inclusion criteria. We identified level 1 evidence for sexual adverse effects as a primary outcome in patients taking finasteride. LIMITATIONS: Many included studies were limited by sample size and methodology. CONCLUSION: The information in this review may serve as a reference of adverse effects when deciding on a therapeutic agent and a guide to help identify patients to screen for sexual dysfunction.
BACKGROUND: Prescription medications are among the most common causes of sexual dysfunction, and patients are often hesitant to seek help when experiencing these symptoms. OBJECTIVE: In this review, we identify the available evidence of sexual adverse effects in men using systemic dermatologic medications and suggest screening protocols and actions that may improve a patient's symptoms where possible. METHODS: A systematic review was conducted of all articles in the PubMed database published from the time of inception to May 2018 to identify studies evaluating the use of systemic dermatologic medications in men with evidence of sexual adverse effects. Subsequently, a secondary in-depth literature review was performed for each individual medication. RESULTS: There were 5497 articles reviewed in the primary systematic review, and 59 articles covering 11 systemic dermatologic medications met inclusion criteria. We identified level 1 evidence for sexual adverse effects as a primary outcome in patients taking finasteride. LIMITATIONS: Many included studies were limited by sample size and methodology. CONCLUSION: The information in this review may serve as a reference of adverse effects when deciding on a therapeutic agent and a guide to help identify patients to screen for sexual dysfunction.
Authors: Francesco Pallotti; Giulia Senofonte; Marianna Pelloni; Francesco Cargnelutti; Tania Carlini; Antonio F Radicioni; Alfredo Rossi; Andrea Lenzi; Donatella Paoli; Francesco Lombardo Journal: Endocrine Date: 2020-02-12 Impact factor: 3.633